Citations

Mayo Clinic

Showing 10 of 108599 citations.

Right ventricular pacemaker lead position is associated with differences in long‐term outcomes and complications
Witt, Chance M. , Lenz, Charles J., Shih, Henry, Ebrille, Elisa , Rosenbaum, Andrew , Zyl, Martin van , Aung, Htin , Manocha, Kevin K. , Deshmukh, Abhishek , Hodge, David O. , Mulpuru, Siva K. , Cha, Yong‐Mei , Espinosa, Raúl E. , Asirvatham, Samuel J. , McLeod, Christopher J. , Asirvatham, Samuel J

Journal of Cardiovascular Electrophysiology | May 25, 2017 | Volume: 28 | Issue: 8 | Pages: 924-930

10.1111/jce.13256 | PMID 28543771 Get It

AbstractIntroductionCardiac pacing from the right ventricular apex is associated with detrimental long‐term effects and nonapical pacing locations may be associated with improved outcomes. There is little data regarding complications with nonapical lead positions. The aim of this study was to assess long‐term outcomes and lead‐related complications associated with differing ventricular lead tip position.Methods and resultsAll adult patients who underwent dual‐chamber pacemaker implantation from 2004 to 2014 were included if they had postprocedure chest radiographs amenable to lead position determination. Long‐term outcomes and lead‐related complication rates were recorded. These were compared at 5 years between: (1) apical and septal leads, (2) apical and nonseptal nonapical (NSNA), and (3) apical and septal with >40% ventricular pacing. We retrospectively evaluated 3,450 patients, which included 238 with a septal position and 733 with NSNA lead positions. Septal lead position was associated with a lower mortality compared to apical leads (24% vs. 31%, P = 0.02). In patients with greater than 40% pacing, septal leads were associated with significantly higher rates of incident atrial fibrillation compared to apical leads (49% vs. 34%, P = 0.04). NSNA positions were associated with a significantly higher rate of lead dislodgement (4% vs. 2%, P = 0.005) and need for revision (8% vs. 5%, P = 0.005).ConclusionsSeptal pacemaker lead position is associated with a lower mortality compared to apically placed leads, but a higher incidence of atrial fibrillation with higher percentage ventricular pacing. NSNA lead locations are associated with more complications and should be avoided.
Nanotherapeutic systems for local treatment of brain tumors
Chakroun, Rami W. , Zhang, Pengcheng , Lin, Ran , Schiapparelli, Paula , Quiñones‐Hinojosa, Alfredo , Cui, Honggang

WIREs Nanomedicine and Nanobiotechnology | May 25, 2017 | Volume: 10 | Issue: 1 | Pages: No page available

10.1002/wnan.1479 | PMID 28544801 Get It

Malignant brain tumor, including the most common type glioblastoma, are histologically heterogeneous and invasive tumors known as the most devastating neoplasms with high morbidity and mortality. Despite multimodal treatment including surgery, radiotherapy, chemotherapy, and immunotherapy, the disease inevitably recurs and is fatal. This lack of curative options has motivated researchers to explore new treatment strategies and to develop new drug delivery systems (DDSs); however, the unique anatomical, physiological, and pathological features of brain tumors greatly limit the effectiveness of conventional chemotherapy. In this context, we review the recent progress in the development of nanoparticle‐basedDDSsaiming to address the key challenges in transporting sufficient amount of therapeutic agents into the brain tumor areas while minimizing the potential side effects. We first provide an overview of the standard treatments currently used in the clinic for the management of brain cancers, discussing the effectiveness and limitations of each therapy. We then provide an in‐depth review of nanotherapeutic systems that are intended to bypass the blood–brain barrier, overcome multidrug resistance, infiltrate larger tumorous tissue areas, and/or release therapeutic agents in a controlled manner.WIREs Nanomed Nanobiotechnol2018, 10:e1479. doi: 10.1002/wnan.1479This article is categorized under:Implantable Materials and Surgical Technologies > Nanomaterials and ImplantsTherapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Ileocecal vascularized lymph node transfer for the treatment of extremity lymphedema: A case report
Ciudad, Pedro , Manrique, Oscar J. , Agko, Mouchammed , Liu, En‐Wei , Chang, Wei‐Ling , Yeo, Matthew Sze‐Wei , Huang, Tony Chieh‐Ting , Chilgar, Ram M., Chen, Hung‐Chi , Chen, Hung‐Chi , Mouchammed, Agko , Huang, Tony C T

Microsurgery | May 25, 2017 | Volume: 39 | Issue: 1 | Pages: 81-84

10.1002/micr.30186 | PMID 28543381 Get It

Vascularized lymph node (VLN) transfer has been of high interest in the past decade for the treatment of lymphedema, since it has been shown to be effective in reducing limb volumes, decreasing infectious episodes and improving quality of life. Multiple donor sites have been described in the quest for the optimal one. Herein, we describe a novel lymph node flap option based on the ileocolic artery and vein. The ileocecal vascularized lymph node (IC‐VLN) flap was used in the management of a 33‐year‐old male patient with lower extremity lymphedema secondary to left inguinal trauma. The patient had previously underwent a pedicled omentum flap transposition with minimal improvement in limb size and persistent episodes of infection. At 15 month follow‐up, the IC‐VLN flap improved the lymphatic drainage in the affected limb with a mean limb circumference reduction rate of 26.3%. No donor site complications or further episodes of infection were noted. According to our findings, the IC‐VLN flap may be another option for VLN transfer in very selected cases. Nevertheless, larger series with a longer follow‐up are required to analyze the efficacy and long‐term results of this flap.
When Should Emergent Imaging Be Performed?—Reply
Chen, John J. , Fang, Chengbo , Leavitt, Jacqueline A., Chen, John J

JAMA Ophthalmology | May 25, 2017 | Volume: 135 | Issue: 7 | Pages: 820

10.1001/jamaophthalmol.2017.1430 | PMID 28542672 Get It

Glomerular Hyperfiltration in Obese African American Hypertensive Patients Is Associated With Elevated Urinary Mitochondrial-DNA Copy Number
Eirin, Alfonso , Saad, Ahmed , Woollard, John R. , Juncos, Luis A. , Calhoun, David A. , Textor, Stephen C., Lerman, Lilach O. , Tang, Hui Jun , Lerman, Amir , Eirin, Alfonso , Juncos, Luis A

American Journal of Hypertension | May 25, 2017 | Volume: 30 | Issue: 11 | Pages: 1112-1119

10.1093/ajh/hpx103 | PMID 28641368 Get It

Endoscopic management of bile leaks after liver transplantation: An analysis of two high-volume transplant centers
Sendino, Oriol , Fernández-Simón, Alejandro , Law, Ryan , Dayyeh, Barham Abu, Leise, Michael D. , Chavez-Rivera, Karina, Córdova, Henry , Colmenero, Jordi , Crespo, Gonzalo , Miguel, Cristina Rodríguez de , Fondevila, Constantino , Llach, Josep, Navasa, Miquel , Baron, Todd H. , Abu Dayyeh, Barham, Leise, Michael, Llach, Josep, Cárdenas, Andrés , Crespo, Gonzalo , Colmenero, Jordi

United European Gastroenterology Journal | May 25, 2017 | Volume: 6 | Issue: 1 | Pages: 89-96

10.1177/2050640617712869 | PMID 29435318 Get It

Background Bile leak after liver transplantation (LT) is commonly treated with endoscopic retrograde cholangiopancreatography (ERCP); however, there are limited data regarding the optimal treatment strategy. Objective We aimed to examine the role of ERCP in LT recipients with bile leaks at two large institutions. Methods We reviewed all ERCPs performed in LT recipients with bile leak and duct-to-duct biliary anastomosis at two high-volume transplant centers. Results Eighty patients were included. Forty-seven (59%) patients underwent ERCP with plastic stent placement (with or without sphincterotomy) and 33 patients (41%) underwent sphincterotomy alone. Complete resolution was obtained in 94% of the stent group vs. 58% of the sphincterotomy group ( p < 0.01). There was no difference in three-month survival among both groups. Percutaneous transhepatic therapy and surgery were required in 4% and 6% in the stent group vs. 12% and 42% in the sphincterotomy group, respectively ( p = 0.22 and p < 0.001). The only predictive factor of bile leak resolution was stent placement. Conclusion ERCP with plastic stent placement is highly successful and more effective than sphincterotomy alone for post-LT bile leak treatment. These results indicate that ERCP and plastic stent placement should be considered the standard of care for the treatment of bile leaks in LT.
TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling
Masyuk, Anatoliy I. , Pisarello, María J. Lorenzo , Howard, Brynn N., Huang, Bing , Lee, Pui Yuen , Sergienko, Eduard , Ardecky, Robert, Chung, Thomas D.Y. , Pinkerton, Anthony B. , Masyuk, Tatyana V. , Lorenzo Pisarello, Maria, Huang, Bing Q, Fung, Xavier, Fung, Xavier C. C. , LaRusso, Nicholas F.

Hepatology | May 25, 2017 | Volume: 66 | Issue: 4 | Pages: 1197-1218

10.1002/hep.29284 | PMID 28543567 Get It

Hepatic cystogenesis in polycystic liver disease is associated with increased levels of cyclic adenosine monophosphate (cAMP) in cholangiocytes lining liver cysts. Takeda G protein receptor 5 (TGR5), a G protein–coupled bile acid receptor, is linked to cAMP and expressed in cholangiocytes. Therefore, we hypothesized that TGR5 might contribute to disease progression. We examined expression of TGR5 and Gα proteins in cultured cholangiocytes and in livers of animal models and humans with polycystic liver disease. In vitro, we assessed cholangiocyte proliferation, cAMP levels, and cyst growth in response to (1) TGR5 agonists (taurolithocholic acid, oleanolic acid [OA], and two synthetic compounds), (2) a novel TGR5 antagonist (m‐tolyl 5‐chloro‐2‐[ethylsulfonyl] pyrimidine‐4‐carboxylate [SBI‐115]), and (3) a combination of SBI‐115 and pasireotide, a somatostatin receptor analogue. In vivo, we examined hepatic cystogenesis in OA‐treated polycystic kidney rats and after genetic elimination of TGR5 in double mutant TGR5−/− ;Pkhd1del2/del2 mice. Compared to control, expression of TGR5 and Gαs (but not Gαi and Gαq) proteins was increased 2‐fold to 3‐fold in cystic cholangiocytes in vitro and in vivo. In vitro, TGR5 stimulation enhanced cAMP production, cell proliferation, and cyst growth by ∼40%; these effects were abolished after TGR5 reduction by short hairpin RNA. OA increased cystogenesis in polycystic kidney rats by 35%; in contrast, hepatic cystic areas were decreased by 45% in TGR5‐deficient TGR5−/−;Pkhd1del2/del2 mice. TGR5 expression and its colocalization with Gαs were increased ∼2‐fold upon OA treatment. Levels of cAMP, cell proliferation, and cyst growth in vitro were decreased by ∼30% in cystic cholangiocytes after treatment with SBI‐115 alone and by ∼50% when SBI‐115 was combined with pasireotide. Conclusion: TGR5 contributes to hepatic cystogenesis by increasing cAMP and enhancing cholangiocyte proliferation; our data suggest that a TGR5 antagonist alone or concurrently with somatostatin receptor agonists represents a potential therapeutic approach in polycystic liver disease. (Hepatology 2017;66:1197‐1218).
Advances Afoot in Microbiology
Patel, Robin , Karon, Brad S. , Patel, Robin

Journal of Clinical Microbiology | May 25, 2017 | Volume: 55 | Issue: 7 | Pages: 1984-1988

10.1128/jcm.00664-17 | PMID 28539341 Get It

ABSTRACT In 2016, the American Academy of Microbiology convened a colloquium to examine point-of-care (POC) microbiology testing and to evaluate its effects on clinical microbiology. Colloquium participants included representatives from clinical microbiology laboratories, industry, and the government, who together made recommendations regarding the implementation, oversight, and evaluation of POC microbiology testing. The colloquium report is timely and well written (V. Dolen et al., Changing Diagnostic Paradigms for Microbiology , 2017, https://www.asm.org/index.php/colloquium-reports/item/6421-changing-diagnostic-paradigms-for-microbiology?utm_source=Commentary&utm_medium=referral&utm_campaign=diagnostics ). Emerging POC microbiology tests, especially nucleic acid amplification tests, have the potential to advance medical care.
Enhanced Recovery Program and Length of Stay After Laparotomy on a Gynecologic Oncology Service: A Randomized Controlled Trial
Nelson, Gregg , Ramírez, Pedro T. , Ljungqvist, Olle , Dowdy, Sean C. , Nelson, Gregg S

Obstetrics & Gynecology | May 24, 2017 | Volume: 129 | Issue: 6 | Pages: 1139-1139

10.1097/aog.0000000000002083 | PMID 28538481 Get It

Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure–Lowering Effects of Latanoprost
Roddy, Gavin W. , Viker, Kimberly, Winkler, Nelson S., Bahler, Cindy K., Holman, Bradley H., Sheikh‐Hamad, David , Chowdhury, Uttio Roy, Fautsch, Michael P. , Viker, Kimberly B, Roy Chowdhury, Uttio, Stamer, William Daniel

Investigative Opthalmology & Visual Science | May 24, 2017 | Volume: 58 | Issue: 5 | Pages: 2715

10.1167/iovs.16-21004 | PMID 28538979 Get It